| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 44.90 | 48 |
| Intrinsic value (DCF) | 2040.52 | 6614 |
| Graham-Dodd Method | 1.80 | -94 |
| Graham Formula | 5.80 | -81 |
TG Therapeutics, Inc. (LSE: 0VGI.L) is a commercial-stage biopharmaceutical company headquartered in New York, specializing in innovative treatments for B-cell malignancies and autoimmune diseases. The company’s flagship candidates include Ublituximab, a glycoengineered monoclonal antibody targeting B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and multiple sclerosis, and Umbralisib, a dual PI3K-delta/CK1-epsilon inhibitor for hematologic cancers. Additionally, TG Therapeutics is advancing Cosibelimab, a PD-L1 inhibitor, and BTK inhibitor TG-1701, positioning itself in the competitive immuno-oncology and hematology markets. With strategic collaborations with Checkpoint Therapeutics, Jiangsu Hengrui Medicine, and others, TG Therapeutics leverages partnerships to enhance its R&D pipeline. The company operates in the high-growth pharmaceutical sector, focusing on unmet medical needs in oncology and autoimmune disorders, making it a key player in precision medicine.
TG Therapeutics presents a high-risk, high-reward investment opportunity due to its focus on niche oncology and autoimmune therapies. With a market cap of $4.65B and a beta of 2.2, the stock is highly volatile, reflecting its clinical-stage pipeline risks. Revenue ($329M) and net income ($23.4M) in FY2024 suggest commercialization progress, but negative operating cash flow (-$40.5M) indicates ongoing R&D expenses. The lack of dividends reinforces its growth-centric strategy. Investors should weigh its promising pipeline (e.g., Ublituximab for MS) against regulatory risks and competition in the crowded BTK/PI3K inhibitor space.
TG Therapeutics competes in the specialized markets of B-cell malignancies and autoimmune diseases, where differentiation is critical. Its competitive edge lies in Ublituximab’s glycoengineering, which may offer efficacy/safety advantages over rivals like Roche’s Rituxan. However, Umbralisib faces stiff competition from PI3K inhibitors such as Gilead’s Zydelig, which has safety concerns but first-mover advantage. The PD-L1 inhibitor Cosibelimab enters a saturated checkpoint inhibitor market dominated by Merck’s Keytruda. TG’s partnerships (e.g., with Hengrui) provide R&D support but dilute control. Financially, its modest revenue base and debt ($254M) limit scalability versus larger peers. The company’s focus on niche indications (e.g., marginal zone lymphoma) mitigates direct competition but caps market potential. Success hinges on clinical differentiation and pipeline execution.